COMMUNIQUÉS West-GlobeNewswire

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
27/04/2026
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of [...]
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
27/04/2026
-- Company’s extended-release formulation of zinc acetate will be compared to GALZIN® (zinc acetate) and a placebo for the treatment of Wilson disease -- DEER PARK, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Eton [...]
Conference to focus on how artificial intelligence can dramatically reduce workplace injuries
27/04/2026
MARKHAM, Ontario, April 27, 2026 (GLOBE NEWSWIRE) -- The third annual New Horizons in Safety Summit - From Outputs to Outcomes - to be hosted by 4S Consulting will be held on May 7 th . . The conference will bring [...]
Every minute counts: EAACI calls for urgent action to make schools safe for children at risk of anaphylaxis
27/04/2026
At the Spanish Congress of Deputies, EAACI President María José Torres backed a joint manifesto with AEPNAA, SEAIC, and SEICAP, calling for urgent action on school protocols, staff training, and access to life-saving [...]
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
27/04/2026
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated, CDK4/6- [...]
KFSH Highlights Scalable AI Integration Model at C3 Davos of Healthcare™ Silicon Valley Summit
27/04/2026
SUNNYVALE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- As global health systems shift from isolated digital initiatives to integrated, data-driven care models, King Faisal Specialist Hospital & Research Centre (KFSH [...]
Composition of the Nomination Committee of Orion Corporation
27/04/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 27 APRIL 2026 at 12:00 EEST Composition of the Nomination Committee of Orion Corporation The Board of [...]
Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma
27/04/2026
Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily pretreated PTCL population Responses highest in angioimmunoblastic T-cell [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
27/04/2026
COPENHAGEN, Denmark, April 27, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up [...]
Novo Nordisk A/S - share repurchase programme
27/04/2026
Bagsværd, Denmark, 27 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
27/04/2026
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, [...]
Fangzhou Publishes 2025 Annual Report, Advancing AI-Powered Chronic Care Strategy for 2026
27/04/2026
SHANGHAI, April 27, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, published its 2025 Annual Report, following the [...]
OSE Immunotherapeutics se félicite de l'octroi de la désignation de médicament orphelin par la FDA du pegrizeprument (VEL-101) pour la prévention du rejet d’organe dans la transplantation cardiaque
27/04/2026
Nantes, le 27 avril, 7h30 CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo : OSE) se félicite aujourd’hui de l’annonce faite par son partenaire Veloxis Pharmaceuticals, Inc., rapportant que la U.S. Food and [...]
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
27/04/2026
Nantes, France, April 27, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today welcomes the announcement by its partner Veloxis Pharmaceuticals, Inc. that the U.S. Food and Drug [...]
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
27/04/2026
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi 1 Rhapsido recommended in 2026 International Urticaria [...]
Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU
27/04/2026
Pratteln, Switzerland, April 27, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive [...]
Dark Horse Consulting Group and Porton Advanced Announce Memorandum of Understanding Providing a Streamlined Path to Conducting IITs in China
27/04/2026
WALNUT CREEK, Calif. and SUZHOU, China, April 26, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Porton Advanced, a [...]
C3 Davos of Healthcare™ Silicon Valley Summit Opens Tomorrow in Sunnyvale with KFSH
26/04/2026
SUNNYVALE, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- The C3 Davos of Healthcare™ Silicon Valley Summit will begin tomorrow at the Plug and Play Tech Center in Sunnyvale, California, under the theme “Healthtech [...]
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
26/04/2026
MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the [...]

Pages